ANGPTL3 Inhibitor Market Set for Robust Growth During the Forecast Period (2025-2034) Across 7MM Owing to the Rising Demand for Novel Lipid-Lowering Therapies | DelveInsight [Yahoo! Financ...
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
Additionally, the anticipated launch of emerging therapies by key companies such as Arrowhead Pharmaceuticals, Eli Lilly and Company, Verve Therapeutics, Regeneron Pharmaceuticals, and others will further boost the market. LAS VEGAS April 16, 2025 /PRNewswire/ -- DelveInsight's ANGPTL3 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging ANGPTL3 inhibitor, market share of individual therapies, and current and forecasted ANGPTL3 inhibitor market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the ANGPTL3 Inhibitor Market Report As per DelveInsight's analysis, the total market size of ANGPTL3 inhibitor in the 7MM is expected to surge significantly by 2034. In the assessment done by DelveInsight, the estimated total ASCVD diagnosed prevalent cases in t
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an "overweight" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Business Wire
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an "outperform" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a "buy" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other TauopathiesBusiness Wire
ARWR
Earnings
- 11/25/25 - Miss
ARWR
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- ARWR's page on the SEC website